☰

Natalya Danchenko, Ph.D. - Publications

Affiliations: 
2005 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Public Health, Medicine and Surgery
Tree Info Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Review of Pharmacoeconomics & Outcomes Research. PMID 33307885 DOI: 10.1080/14737167.2021.1855979  0.34
2020 Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Review of Pharmacoeconomics & Outcomes Research. PMID 33307885 DOI: 10.1080/14737167.2021.1855979  0.34
2018 Lam RW, Lamy FX, Danchenko N, Yarlas A, White MK, Rive B, Saragoussi D. Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder. Neuropsychiatric Disease and Treatment. 14: 2861-2877. PMID 30464471 DOI: 10.2147/Ndt.S175188  0.491
2017 Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 28663124 DOI: 10.1016/J.Euroneuro.2017.05.009  0.414
2017 Young AH, Evitt L, Brignone M, Diamand F, Atsou K, Campbell R, Cure S, Danchenko N. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. Journal of Affective Disorders. 218: 291-298. PMID 28478358 DOI: 10.1016/J.Jad.2017.04.019  0.502
2017 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain and Behavior. 7: e00622. PMID 28293465 DOI: 10.1002/Brb3.622  0.506
2017 François C, Nielsen R, Danchenko N, Williams V, Lançon C. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine. Current Medical Research and Opinion. 1-24. PMID 28277865 DOI: 10.1080/03007995.2017.1299701  0.422
2016 Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, Aalto-Setälä M, Danchenko N, Koponen HJ, Kolasa K. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research. PMID 27680105 DOI: 10.1080/14737167.2017.1240617  0.508
2016 Williams V, François C, Danchenko N, Nelson L, Williams N, Yarr S, DiBenedetti D, Lançon C. Psychometric validation of the depression and family functioning scale. Current Medical Research and Opinion. 1-12. PMID 26700415 DOI: 10.1185/03007995.2015.1135111  0.436
2016 Evitt L, Danchenko N, Atsou K, Brignone M, Diamand F, Campbell R. Cost-Effectiveness Evaluation of Vortioxetine in Major Depressive Episode in the UK Setting Value in Health. 19. DOI: 10.1016/J.Jval.2016.09.1039  0.46
2015 Florea I, Danchenko N, Brignone M, Loft H, Rive B, Abetz-Webb L. The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. Clinical Therapeutics. 37: 2309-2323.e6. PMID 26346592 DOI: 10.1016/J.Clinthera.2015.08.008  0.376
2015 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Sheehan DV, Jacobsen PL. P.2.f.005 Vortioxetine effects on overall patient functioning in patients with major depressive disorder European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30584-8  0.447
2015 Francois C, Nielsen R, Danchenko N, Williams V, Lancon C. The effect of Vortioxetine on family functioning in adults with major depressive disorder Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.724  0.46
2015 Diamand F, Danchenko N, Brignone M, Rive B, Perez V, Ereshefsky L, Francois C, Merikle E. Relative Efficacy and Tolerability of Vortioxetine versus Approved Antidepressants for Major depressive Disorder: a meta-regression of Clinical Trials Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.719  0.454
2015 Francois C, Danchenko N, Williams V, Nelsen L, Williams NJ, Yarr S, DiBenedetti DB, Lancon C. Validation of the Depression and Family Functioning Scale (Dffs) Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.150  0.428
2014 Soini EJ, Hallinen T, Brignone M, Despiégel N, Aalto-Setälä M, Danchenko N, Kolasa K. Cost-Utility of Vortioxetine in the Treatment of Major Depressive Disorder: Comparison with Agomelatine, Bupropion, Sertraline and Venlafaxine in the Finnish Setting. Value in Health. 17. PMID 27201284 DOI: 10.1016/J.Jval.2014.08.1267  0.497
2013 Lensberg BR, Drummond MF, Danchenko N, Despiégel N, François C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoeconomics and Outcomes Research : Ceor. 5: 565-73. PMID 24273412 DOI: 10.2147/Ceor.S44866  0.318
2013 Fehnel SE, Forsyth BH, Dibenedetti DB, Danchenko N, François C, Brevig T. Patient-centered assessment of cognitive symptoms of depression. Cns Spectrums. 1-10. PMID 24067243 DOI: 10.1017/S1092852913000643  0.4
2013 Lam RW, Saragoussi D, Danchenko N, Rive B, Lamy FX, Brevig T. Psychometric Validation of Perceived Deficits Questionnaire – Depression (PDQ-D) in Patients with Major Depressive Disorder (MDD) Value in Health. 16. DOI: 10.1016/J.Jval.2013.08.046  0.516
2013 Florea I, Danchenko N, Loft H, Rive B, Pendlebury S, Abetz L. The effect of vortioxetine (LU AA21004) on health-related quality of life (HRQOL) in patients with major depressive disorder (MDD) Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.1601  0.443
2013 Danchenko N, Rive B, Pendlebury S, Abetz L. Assessing health-related quality of life (HRQOL) in major depressive disorder (MDD): Do commonly used instruments meet EMA requirements for psychometric properties and content relevance Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.1598  0.422
2012 Despiégel N, Danchenko N, François C, Lensberg B, Drummond MF. The use and performance of productivity scales to evaluate presenteeism in mood disorders. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 15: 1148-61. PMID 23244819 DOI: 10.1016/J.Jval.2012.08.2206  0.35
2012 Nordström G, Danchenko N, Despiegel N, Marteau F. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 15: 231-9. PMID 22433753 DOI: 10.1016/J.Jval.2011.09.011  0.383
2012 DiBenedetti DB, Danchenko N, François C, Lewis S, Davis KH, Fehnel SE. Development of a family functioning scale for major depressive disorder. Current Medical Research and Opinion. 28: 303-13. PMID 22256800 DOI: 10.1185/03007995.2012.658910  0.504
2012 Greco CM, Li T, Sattar A, Kao AH, Danchenko N, Edmundowicz D, Sutton-Tyrrell K, Tracy RP, Kuller LH, Manzi S. Association between depression and vascular disease in systemic lupus erythematosus. The Journal of Rheumatology. 39: 262-8. PMID 22174200 DOI: 10.3899/Jrheum.110327  0.587
2012 Forsyth B, Fehnel S, Danchenko N, François C, Brevig T. P.2.a.010 Patient-reported cognitive symptoms and a patient-reported outcome measure of cognitive function in depression European Neuropsychopharmacology. 22. DOI: 10.1016/S0924-977X(12)70339-5  0.363
2012 Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. PMH42 Assessing Impacts of Major Depressive Disorder (MDD) on Cognitive Function Value in Health. 15. DOI: 10.1016/J.Jval.2012.08.832  0.466
2011 Lançon C, DiBenedetti DB, Lewis S, Davis K, Danchenko N, François C. Pmh53 Assessing The Impact Of Major Depressive Disorder (Mdd) On Family Functioning: Development Of The Depression And Family Functioning Scale Value in Health. 14. DOI: 10.1016/J.Jval.2011.02.1077  0.482
2010 Nordström G, Despiegel N, Marteau F, Danchenko N, Maman K. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. Journal of Medical Economics. 13: 516-26. PMID 20698748 DOI: 10.3111/13696998.2010.506371  0.432
2009 Xie F, Despiegel N, Danchenko N, Hansen K. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice. 13: 59-69. PMID 24946123 DOI: 10.1080/13651500802450506  0.443
2009 Greco CM, Kao AH, Sattar A, Danchenko N, Maksimowicz-McKinnon KM, Edmundowicz D, Sutton-Tyrrell K, Tracy RP, Kuller LH, Manzi S. Association between depression and coronary artery calcification in women with systemic lupus erythematosus. Rheumatology (Oxford, England). 48: 576-81. PMID 19286698 DOI: 10.1093/Rheumatology/Kep020  0.612
2009 Rhew EY, Manzi SM, Dyer AR, Kao AH, Danchenko N, Barinas-Mitchell E, Sutton-Tyrrell K, McPherson DD, Pearce W, Edmundowicz D, Kondos GT, Ramsey-Goldman R. Differences in subclinical cardiovascular disease between African American and Caucasian women with systemic lupus erythematosus. Translational Research : the Journal of Laboratory and Clinical Medicine. 153: 51-9. PMID 19138649 DOI: 10.1016/J.Trsl.2008.11.006  0.496
2009 Despiégel N, Danchenko N, Maman K. Pmh25 Cost-Effectiveness Of Escitalopram Versus Venlafaxine In Second-Line Treatment Of Major Depressive Disorder (Mdd) In Sweden Value in Health. 12. DOI: 10.1016/S1098-3015(10)73946-2  0.489
2008 Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmacoeconomics. 26: 969-81. PMID 18850765 DOI: 10.2165/00019053-200826110-00008  0.428
2008 Kao AH, Wasko MC, Krishnaswami S, Wagner J, Edmundowicz D, Shaw P, Cunningham AL, Danchenko N, Sutton-Tyrrell K, Tracy RP, Kuller LH, Manzi S. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. The American Journal of Cardiology. 102: 755-60. PMID 18774002 DOI: 10.1016/J.Amjcard.2008.04.059  0.466
2007 Wade A, Fernandez J, François C, Hansen K, Despiegel N, Danchenko N. Pmh60 A Pharmacoeconomic Comparison Of Escitalopram And Duloxetine In Treatment Of Major Depressive Disorder (Mdd) In The United Kingdom Value in Health. 10. DOI: 10.1016/S1098-3015(10)65110-8  0.496
2007 Danchenko N, Maehlum E, Hansen K, Despiegel N, Holsten F. Pmh28 A Pharmacoeconomic Evaluation Of Escitalopram Vs. Paroxetine In The Treatment Of Generalized Anxiety Disorder In Norway Value in Health. 10. DOI: 10.1016/S1098-3015(10)65078-4  0.35
Show low-probability matches.